MAR 19, 2019 11:23 AM PDT

Efficacy of Cancer Therapeutics is Better When Muscle Mass is Normal

WRITTEN BY: Carmen Leitch

People have been pumping iron to improve their physique for many years, and it’s known that exercise is related to good health. Now scientists have determined that increasing muscle mass could be a life-saver. Researchers at Osaka University found that the loss of skeletal muscles, also known as sarcopenia, is closely related to a lack of responsiveness to therapeutics aimed at advanced non-small cell lung cancer (NSCLC). The findings have been published in Scientific Reports, and are briefly summarized in the video.

Treatments for NSCLC are called programmed cell death (PD-1) inhibitors; they are a relatively new class of drugs that have the potential to combat various types of cancer. They are designed to enhance a patient’s ability to use their own immune system to attack cancer, and as such, depend heavily on the proper function of that patient’s immune system.

Unfortunately, only a small number of patients respond well to these drugs. The Osaka researchers are hopeful that their work will help address this problem. 

“Sarcopenia is a well-known risk factor associated with poor outcomes for several cancer types," said the lead author of the report, Takayuki Shiroyama. "Because muscle degradation is associated with a dysregulated immune response, we wanted to investigate how, in lung cancer patients, sarcopenia impacts the efficacy of PD-1 inhibitor therapy.”

Two lung cancer patients - cross-section of the psoas major muscle (green); non-sarcopenic (left), sarcopenic (right) / Credit: Osaka University

In this study, the scientists assessed the medical records of 42 advanced NSCLC patients who had also been checked for muscle mass to see how well they responded to PD-1 inhibitors. 

“The results were surprisingly emphatic. We found that the treatment outcomes for patients with sarcopenia at the start of therapy were far worse than those without,” revealed the senior author of the work Atsushi Kumanogoh.

The researchers determined that one year after treatment, 38.1 percent of non-sarcopenia patients were in remission but only 10.1 percent of sarcopenia patients had no progression in tumor growth in that same time period.  

“Our findings suggest that baseline skeletal muscle mass has a substantial impact on PD-1 inhibitor efficacy. As such, skeletal muscle mass might be useful for predicting whether treatment is likely to be effective,” explained Shiroyama.

Muscle wasting is commonly observed in patients who have advanced cancer. Some new drugs may help increase skeletal muscle mass, which could be very important to the success of therapeutics.

Patients that will be receiving PD-1 inhibitor therapy may also increase the likelihood that the treatment will be successful if they aim to increase muscle mass before treatment begins.

 

Sources: AAAS/Eurekalert! Via Osaka University, Scientific Reports

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUN 07, 2021
Cardiology
Researchers Find a Way to Improve Outcomes After a Heart Attack
JUN 07, 2021
Researchers Find a Way to Improve Outcomes After a Heart Attack
It's thought that in the United States, there is a heart attack once every 40 seconds, or that each year, about 80,0 ...
JUN 20, 2021
Microbiology
Bacteria Can Shape-Shift to Survive in Different Conditions
JUN 20, 2021
Bacteria Can Shape-Shift to Survive in Different Conditions
Escherichia coli bacteria are known to live in the gut, and they can also sicken people if they contaminate food that ge ...
JUN 28, 2021
Earth & The Environment
Yeast Engineered to Produce Biofuel from Previously Unusable Biomass
JUN 28, 2021
Yeast Engineered to Produce Biofuel from Previously Unusable Biomass
Researchers from the Massachusetts Institute of Technology have found a way to expand biofuel production with geneticall ...
JUL 11, 2021
Microbiology
COVID-19 Delta Variant Seems to Grow Faster & Be More Contagious
JUL 11, 2021
COVID-19 Delta Variant Seems to Grow Faster & Be More Contagious
In October 2020, what's now called the Delta variant of SARS-CoV-2 was first detected. It's now the most prevalent strai ...
JUL 12, 2021
Genetics & Genomics
Vision of Retinitis Pigmentosa Patient Partially Restored by New Therapy
JUL 12, 2021
Vision of Retinitis Pigmentosa Patient Partially Restored by New Therapy
Scientists have been developing gene therapies that can help restore vision that's lost due to a problem with a gene ...
JUL 19, 2021
Microbiology
Engineering a Virus Trap
JUL 19, 2021
Engineering a Virus Trap
Viral infections are difficult to treat - antibiotics only work against bacteria - and there are few effective antibodie ...
Loading Comments...